Journavx is a drug owned by Vertex Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Journavx's patents will be open to challenges from 30 January, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 04, 2040. Details of Journavx's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11834441 | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Journavx's patents.
Latest Legal Activities on Journavx's Patents
Given below is the list of recent legal activities going on the following patents of Journavx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation | 05 Dec, 2023 | US11834441 |
| Patent eGrant Notification | 05 Dec, 2023 | US11834441 |
| Recordation of Patent eGrant | 05 Dec, 2023 | US11834441 |
| Mail Patent eGrant Notification | 05 Dec, 2023 | US11834441 |
| Recordation of Patent Grant Mailed | 05 Dec, 2023 | US11834441 |
| Email Notification | 05 Dec, 2023 | US11834441 |
| Email Notification | 16 Nov, 2023 | US11834441 |
| Issue Notification Mailed | 15 Nov, 2023 | US11834441 |
| Dispatch to FDC | 18 Sep, 2023 | US11834441 |
| Issue Fee Payment Verified | 14 Sep, 2023 | US11834441 |
FDA has granted several exclusivities to Journavx. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Journavx, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Journavx.
Exclusivity Information
Journavx holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Journavx's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
US patents provide insights into the exclusivity only within the United States, but
Journavx is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Journavx's family patents as well as insights into
ongoing legal events
on those patents.
Journavx's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Journavx:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | Vertex Pharmaceuticals Incorporated | NA | COMPLETED
(Sep 1, 2026) | PHASE1 |
| Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | Brigham and Women's Hospital | NA | NOT YET RECRUITING
(Sep 1, 2026) | PHASE3 |
| Suzetrigine Post DIEP | Vanderbilt University Medical Center | NA | NOT YET RECRUITING
(Sep 1, 2026) | PHASE3 |
| Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | Vertex Pharmaceuticals Incorporated | NA | RECRUITING
(Jul 1, 2026) | PHASE3 |
| Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | Icahn School of Medicine at Mount Sinai | NA | RECRUITING
(May 1, 2026) | PHASE3 |
| Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN | Icahn School of Medicine at Mount Sinai | NA | RECRUITING
(Apr 1, 2026) | PHASE3 |
Generic Launch
Generic Release Date:
Journavx's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 04, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Journavx Generics:
There are no approved generic versions for Journavx as of now.
About Journavx
Journavx is a drug owned by Vertex Pharmaceuticals Inc. Journavx uses Suzetrigine as an active ingredient. Journavx was launched by Vertex in 2025.
Approval Date:
Journavx was approved by FDA for market use on 30 January, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Journavx is 30 January, 2025, its NCE-1 date is estimated to be 30 January, 2029.
Active Ingredient:
Journavx uses Suzetrigine as the active ingredient. Check out other Drugs and Companies using Suzetrigine ingredient
Dosage:
Journavx is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Prescription | ORAL |